This phase III trial is comparing the safety and effectiveness of a targeted therapy and standard chemotherapy for the treatment of patients with high-grade epithelial ovarian cancer, primary peritoneal or fallopian tube cancer.
This trial is treating patients with high-grade epithelial ovarian cancer, primary peritoneal or fallopian tube cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Eligible patients will be randomised to receive mirvetuximab soravtansine (MIRV) or the investigator's choice of chemotherapy (paclitaxel, PEGylated liposomal doxorubicin, or topotecan).
Recruiting Hospitals Read More